Details for New Drug Application (NDA): 216984
✉ Email this page to a colleague
NDA 216984 describes TEPYLUTE, which is a drug marketed by Shorla and is included in one NDA. There is one patent protecting this drug. Additional details are available on the TEPYLUTE profile page.
The generic ingredient in TEPYLUTE is thiotepa. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the thiotepa profile page.
The generic ingredient in TEPYLUTE is thiotepa. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the thiotepa profile page.
Medical Subject Heading (MeSH) Categories for 216984
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 15MG/1.5ML (10MG/ML) | ||||
| Approval Date: | Jun 25, 2024 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Aug 16, 2041 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
